Haemonetics (HAE) reported fiscal Q3 adjusted earnings Thursday of $1.19 per diluted share, up from $1.04 a year earlier.
Three analysts polled by FactSet expected $1.11.
Net revenue for the quarter ended Dec. 28 was $348.5 million, up from $336.3 million.
Analysts polled by FactSet expected $353 million.
The company narrowed its fiscal year 2025 adjusted EPS to $4.50 to $4.70 from $4.45 to $4.75. Three analysts surveyed by FactSet are looking for $4.35.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。